el

Analyst upgrades:

• Goldman upgraded SanDisk (NASDAQ: SNDK) to Buy from Neutral and raised their target to $22 from $16 citing the renegotiated royalty agreement with Samsung.
• Goldman also upgraded Starwood Hotels (NYSE: HOT) to Buy from Sell and raised their target to $27 from $11 citing strong operating leverage as RevPAR recovers.
• KeyBanc upgraded Werner Enterprises (NASDAQ: WERN) to Hold from Underweight citing a recent improvement in freight demand.
• J.C. Penney (NYSE: JCP) was upgraded to buy from Underperform at Banc of America/Merrill.
• Savvis (NASDAQ: SVVS) was raised to Outperform from Perform at Oppenheimer.
• Sanofi-Aventis (NYSE: SNY) was upgraded at Citigroup to Buy from Hold.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Activision Blizzard Inc. (NASDAQ: ATVI) Q1 results beat expectations and raised its guidance.
• Alpha Natural Resources Inc. (NYSE: ANR) shares surged after the it reported strong Q1 earnings.
• Archer Daniels Midland Co. (NYSE: ADM) just missed swinging to a loss due to to hefty investment losses.
• CBS Corp. (NYSE: CBS) surprised with a net loss in Q1 as revenue and cash flow declined.
• Chesapeake Energy Corp. (NYSE: CHK) shares fell after it reported disappointing results for the quarter.

Estee Lauder (NYSE: EL - option chain) shares are higher today after the company reported a third-quarter profit of $27.2 million, or 14 cents per share. Excluding one-time items, EL earned 16 cents per share, easily beating analysts' estimates of 5 cents per share. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on EL.

EL opened this morning at $32.89. So far today the stock has hit a low of $32.57 and as of 11:35 is right at its high of $35.15, up $4.02 (12.9%). The chart for EL looks neutral and S&P gives EL a neutral 3 STARS (out of 5) hold ranking.

Revlon (NYSE: REV), a beauty company that counts Avon Products (NYSE: AVP) and The Estee Lauder Companies (NYSE: EL) as colleagues, reported Q1 earnings earlier in the week. I have to admit, I have been bearish on this company for a long time. I still am. I just don't think this stock is a sound place for your portfolio dollars, even though the company did post a much more beauteous profit picture.

Sales decreased a little, but if you exclude currency effects, they rose a weak 3.8%. More impressively, Revlon said that it earned $0.25 per share. That's compared to a net loss of $0.05 per share in the year-ago period. Okay, I concede, that was a pretty good performance. It was partly driven by lower interest expenses and a benefit derived from the repurchase of some senior notes. Free cash flow also saw a gain.

Just as foreclosures account for a record share of the real estate market, foreclosed companies are also one of the few areas of activity in the private equity space.

Sun Capital Partners took Stila Cosmetics private back in 2006, but defaulted on loans from Wachovia and CIT Group (NYSE: CIT) -- leading those lenders to foreclose on the company.

Now Stila has been sold to New York private equity firm Patriarch Partners for an undisclosed sum sure to be considerably lower than what Sun Capital paid when it bought the brand from Estee Lauder (NYSE: EL), which originally purchased the company from founder Jeanine Lobell back in 1999.

Analyst upgrades:

• Citigroup upgraded Blue Nile (NASDAQ: NILE) shares to Buy from Hold on valuation following the recent sell-off as they believe weakening fundamentals have been factored into estimates and that Blue Nile should benefit from the recent softening of diamond prices. The firm raised its target price to $30 from $20.
  
• Baird upgraded AmSurg (NASDAQ: AMSG) to Outperform from Neutral based on valuation, potential upside from in-line results, good visibility, and FCF yield.
  
• Oppenheimer upgraded DryShips (NASDAQ: DRYS) to Perform from Underperform on valuation following the recent weakness and believes the company is at least halfway through its $500M equity offering.
• UAL Corp (NASDAQ: UAUA) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Mylan (NASDAQ: MYL) was upgraded to Overweight from Equal Weight at Barclays.
  
• Exxon Mobil (NYSE: XOM) was lifted at Deutsche Bank to Buy from Hold.

We are at the start of a new and historic presidency. Americans tend to be optimistic and like to look forward to a better future. But before we get too far down the road, let's take one last look in the rear-view mirror.

How many times have we looked at the outgoing president and remarked at how fast the office aged him? How gray, old and tired he looks.

The presidency is a tough job. Living through this stock market seems equally tough.

Sure, Presidents' Day is supposed to celebrate two of the United States' greatest leaders, George Washington and Abraham Lincoln, but that's not what usually happens on the holiday.

What comes to mind when you think of Presidents Day?

Sadly, after Washington and Lincoln, it's mattress sales or furniture bargains. (Car sales are off the radar this year, for obvious reasons.) Not very dignified, but that's just the way it goes.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Anadarko Petroleum Corp. (NYSE: APC) reported that its Q4 profit tripled but it fell short of estimates.
• Biogen Idec Inc. (NASDAQ: BIIB) met earnings estimates but it is getting more pressure from Carl Icahn.
• BP (NYSE: BP) surprised Wall Street with a multibillion dollar Q4 loss due to lower oil prices.
• Cisco Systems Inc. (NASDAQ: CSCO) beat Q2 estimates but warned that incoming orders have declined.
• Dick's Sporting Goods Inc. (NYSE: DKS) reaffirmed its previous Q4 guidance, which pleased investors.
• Estee Lauder Companies Inc. (NYSE: EL) topped Q2 earings estimates and it announced job cuts.
• Humana Inc. (NYSE: HUM) Q4 earnings fell on higher claim expenses and lower investment income.
• JDS Uniphase Corp. (NASDAQ: JDSU) adjusted earnings were in line with estimates but revenue fell.

Amazingly, this week is about to end with stock markets logging gains. Not grim earnings, not glum retail sales, not dismal car sales, nor even weaker-than-expected jobs report seemed able to put a dent in investors' hopes the stimulus bill would pass.

And it's not even the Dow stocks that are leading the advances. As of noon today, the Dow was up about 3% for the week, while the S&P 500 gained about 4.5% and the Nasdaq composite soared some 7%. If you're sorry you didn't take part of this rally, and think perhaps there's more to come after the Senate finally approves the stimulus plan, then BloggingStocks contributors have some ideas for long-term holdings, as well as a few warnings:

Unlike a certain former governor of Illinois, I'm not afraid to admit it when I'm wrong. So, when I noticed that makeup maven Estee Lauder Companies (NYSE: EL) was trading significantly lower today in the wake of its latest earnings report, I decided to take a fresh look at the stock. Was my bullish endorsement back in December completely wrong-headed, or is today's drop just a blip on the charts?

First, let's sum up the quarterly results. EL banked a second-quarter profit of 80 cents per share on $2.04 billion in revenue. The profit number exceeded analysts' expectations by three cents per share, while revenue matched consensus estimates. However, the company warned that third-quarter net sales are expected to drop 2% to 4%, and it announced plans to cut its headcount by 2,000 employees over the next two years -- roughly 6% of its workforce.

Elizabeth Arden's (NASDAQ: RDEN) stock has been shellacked in the last couple of days, continuing a decline that began shortly after it reached a 52-week high of $21.79 in September 2008. RDEN has reached a nine-year low in price at $5.95.

The recent action in the stock should come as no surprise. With retail sales continuing to sour and mall traffic becoming more like Sunday services attendance on a beautiful summer day, it could hardly come as news that Elizabeth Arden would issue a negative earnings alert ahead of the company's second-quarter release of financial results scheduled for Friday.

Cosmetics and fragrances are some of the most discretionary of purchases with the widest range of price points. Consumers have the option of purchasing a less expensive brand or delaying the purchase until a better time. As a result, cosmetic products have reached a historically peak inventory level.

For Elizabeth Arden, those inventory numbers are further evidence of the earnings stress facing the company.

This post is part of a series featuring bargain stocks that are worth a look now. See more Cheap Stocks.

In addition to being a crackerjack equities analyst, I'm also something of a makeup aficionado. Credit my upbringing for this; my mother grew up in the '50s, and even today, she is loathe to so much as check the mail without a full application of liquid eyeliner. So, as you might imagine, I'm quite familiar with Estee Lauder Companies (NYSE: EL).

While it's technically a consumer-goods company, you might have a perception of Estee Lauder as a peddler of upscale cosmetics -- in today's economy, high-priced eyeshadow is unarguably a discretionary expense worth cutting. However, EL's reach is probably broader than you realize. For example, the company owns MAC, a line that caters specifically to professional makeup artists and amateur makeup fetishists. No matter the economic climates, these two constituencies can be counted on to keep shelling out for blush.

Estee Lauder also boasts the lower-priced Clinique line, a staple of many women's' skin-care and cosmetics routines for decades. On the high end, the company sells fragrances by the likes of Tom Ford and Michael Kors -- two names favored by the kind of consumers who do still have disposable income to spare. Plus, its Bumble and bumble brand name is a favorite of professional hair stylists.

Ah, my old buddy Revlon, Inc (NYSE: REV)! Actually, that exclamatory statement is full of sarcasm. Revlon, a beauty-products business whose colleagues include Avon Products, Inc. (NYSE: AVP) and The Estee Lauder Companies Inc. (NYSE: EL), is not a buddy of mine. It is a stock that I really have no intention of buying. The company isn't exactly the most attractive one out there at the moment in terms of fundamentals, but it did have a decent cash-flow statement in the third quarter. Let's check out some numbers.

To begin with, revenues didn't see much growth, as they rose about 1%. Reported net income was $0.57 per diluted share versus a net loss of $0.20 per diluted share in the year-ago period. Unfortunately, that doesn't tell the whole tale. You have to strip out a one-time gain from discontinued operations to get the full story. And you're not going to like it once you do. So, the loss from continuing operations becomes $0.30 per diluted share, which was $0.06 wider than the loss in Q3 2007. Yet, the cash-flow statement does offer a bright spot. Positive operational cash flow of almost $44 million was booked over the last nine months. Last year, Revlon used almost $50 million to fund operations over the nine-month period. Some changes in working capital helped out.

Well, even with the better cash-flow scenario, no, I'm not buying the stock. Revlon is still, in my opinion, a long way off from becoming a great investment idea. I'll need to see more robust growth in the top line and a better profit picture. Sure, for the nine-month period, Revlon did generate a profit of $0.04 per diluted share, but I'm still not convinced. As of this writing, the stock was down 23%. I know it's a bad day in the markets and all, but I wouldn't want to align myself with a company that sees that kind of reaction to earnings. Such a pullback doesn't scream value to me when it comes to Revlon.

Disclosure: I don't own any company mentioned; positions can change at any time.

Estée Lauder Companies (NYSE: EL) is a leading manufacturer and marketer of skin care, makeup, fragrance and hair care products. These are sold in over 140 countries under a variety of established brands, including Estée Lauder, Aramis, Clinique, Bobbi Brown, American Beauty and Grassroots. The firm also operates as a licensee for such fragrance and cosmetic names as Tommy Hilfiger, Kiton, Donna Karan, Daisy Fuentes and Mustang. Estée Lauder sells its products through department stores, specialty retailers, pharmacies and salons, as well as company-owned stores, spas and Web sites. Elizabeth Arden (NASDAQ: RDEN), Procter & Gamble (NYSE: PG) and Revlon (NYSE: REV) are major competitors.

The firm pleased investors earlier in the month, when it reported fiscal Q4 EPS of 61 cents and revenues of $2.01 billion. Analysts had been looking for 56 cents and $1.93 billion. The CEO noted that strategic investments have enabled the company to continue building worldwide share, as it leverages opportunities in emerging markets. Management also guided Q1 EPS to 18-25 cents (24 cent consensus), FY09 EPS to $2.57-$2.72 ($2.66 consensus) and FY09 revenues to about $8.38-$8.54 billion ($8.38B consensus).